Ilaria Silvestri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ilaria Silvestri has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Francesca Fata
IRBM S.p.A., Via Pontina Km 30.600, 00071, Pomezia, Italy
4 shared publications - Matteo Ardini
Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy
4 shared publications - David Lee Williams
Department of Microbial Pathogens and Immunity, Rush University Medical Center, 1735 West Harrison Street, Chicago, IL 60612, USA
3 shared publications - Francesco Angelucci
Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
3 shared publications - Rodolfo Ippoliti
Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
3 shared publications Andrea Bellelli
Dept. of Biochemical Sciences, Sapienza University of Rome, Italy
2 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Springer Nature in Scientific Reports
Exploring the selectivity of molecules targeting the carbohydrate binding site in galectins
- 9 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessExploring the selectivity of molecules targeting the carbohydrate binding site in galectins
- Open Access
- 31 March 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Structure-based identification of the first non-covalent thioredoxin reductase inhibitor with proven ADMET suitability
Thioredoxin reductase 1 (TrxR1), a selenoprotein enzyme crucial for redox homeostasis in mammals, has emerged as a promising target for anticancer therapy. Herein we present the first non-covalent TrxR1 inhibitor, identified through an integrated experimental and computational approach. After identifying a plausible druggable cavity, a molecular docking-based virtual screening of over 90,000 lead-like compounds was performed. The selected compounds were evaluated for their impact on TrxR1 activity, leading to the identification of the most promising candidate, C55. The identified compound, already proved to be free from potential ADMET concerns, inhibits TrxR1 in a dose-dependent manner, with an IC50 value in the micromolar range. C55's activity was confirmed across multiple cancer cell lines, including HepG2, Huh7, MCF-7, and MDA-MB-231 cells. As the first metal-free organic molecule capable of non-covalently inhibiting TrxR1, C55 represents a significant breakthrough, offering a solid foundation for hit-to-lead optimization and the development of new anticancer drug candidates.
- 31 March 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessStructure-based identification of the first non-covalent thioredoxin reductase inhibitor with proven ADMET suitability
Thioredoxin reductase 1 (TrxR1), a selenoprotein enzyme crucial for redox homeostasis in mammals, has emerged as a promising target for anticancer therapy. Herein we present the first non-covalent TrxR1 inhibitor, identified through an integrated experimental and computational approach. After identifying a plausible druggable cavity, a molecular docking-based virtual screening of over 90,000 lead-like compounds was performed. The selected compounds were evaluated for their impact on TrxR1 activity, leading to the identification of the most promising candidate, C55. The identified compound, already proved to be free from potential ADMET concerns, inhibits TrxR1 in a dose-dependent manner, with an IC50 value in the micromolar range. C55's activity was confirmed across multiple cancer cell lines, including HepG2, Huh7, MCF-7, and MDA-MB-231 cells. As the first metal-free organic molecule capable of non-covalently inhibiting TrxR1, C55 represents a significant breakthrough, offering a solid foundation for hit-to-lead optimization and the development of new anticancer drug candidates.
- Open Access
- 19 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Targeting the conserved active site of splicing machines with specific and selective small molecule modulators
The self-splicing group II introns are bacterial and organellar ancestors of the nuclear spliceosome and retro-transposable elements of pharmacological and biotechnological importance. Integrating enzymatic, crystallographic, and simulation studies, we demonstrate how these introns recognize small molecules through their conserved active site. These RNA-binding small molecules selectively inhibit the two steps of splicing by adopting distinctive poses at different stages of catalysis, and by preventing crucial active site conformational changes that are essential for splicing progression. Our data exemplify the enormous power of RNA binders to mechanistically probe vital cellular pathways. Most importantly, by proving that the evolutionarily-conserved RNA core of splicing machines can recognize small molecules specifically, our work provides a solid basis for the rational design of splicing modulators not only against bacterial and organellar introns, but also against the human spliceosome, which is a validated drug target for the treatment of congenital diseases and cancers.
- 19 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessTargeting the conserved active site of splicing machines with specific and selective small molecule modulators
The self-splicing group II introns are bacterial and organellar ancestors of the nuclear spliceosome and retro-transposable elements of pharmacological and biotechnological importance. Integrating enzymatic, crystallographic, and simulation studies, we demonstrate how these introns recognize small molecules through their conserved active site. These RNA-binding small molecules selectively inhibit the two steps of splicing by adopting distinctive poses at different stages of catalysis, and by preventing crucial active site conformational changes that are essential for splicing progression. Our data exemplify the enormous power of RNA binders to mechanistically probe vital cellular pathways. Most importantly, by proving that the evolutionarily-conserved RNA core of splicing machines can recognize small molecules specifically, our work provides a solid basis for the rational design of splicing modulators not only against bacterial and organellar introns, but also against the human spliceosome, which is a validated drug target for the treatment of congenital diseases and cancers.
- Open Access
Targeting the conserved active site of splicing machines with specific and selective small molecule modulators
The self-splicing group II introns are bacterial and organellar ancestors of the nuclear spliceosome and retro-transposable elements of pharmacological and biotechnological importance. Integrating enzymatic, crystallographic, and simulation studies, we demonstrate how these introns recognize small molecules through their conserved active site. These RNA-binding small molecules selectively inhibit the two steps of splicing by adopting distinctive poses at different stages of catalysis, and by preventing crucial active site conformational changes that are essential for splicing progression. Our data exemplify the enormous power of RNA binders to mechanistically probe vital cellular pathways. Most importantly, by proving that the evolutionarily-conserved RNA core of splicing machines can recognize small molecules specifically, our work puts solid bases for the rational design of splicing modulators not only against bacterial and organellar introns, but also against the human spliceosome, which is a validated drug target for the treatment of congenital diseases and cancers.
Open AccessTargeting the conserved active site of splicing machines with specific and selective small molecule modulators
The self-splicing group II introns are bacterial and organellar ancestors of the nuclear spliceosome and retro-transposable elements of pharmacological and biotechnological importance. Integrating enzymatic, crystallographic, and simulation studies, we demonstrate how these introns recognize small molecules through their conserved active site. These RNA-binding small molecules selectively inhibit the two steps of splicing by adopting distinctive poses at different stages of catalysis, and by preventing crucial active site conformational changes that are essential for splicing progression. Our data exemplify the enormous power of RNA binders to mechanistically probe vital cellular pathways. Most importantly, by proving that the evolutionarily-conserved RNA core of splicing machines can recognize small molecules specifically, our work puts solid bases for the rational design of splicing modulators not only against bacterial and organellar introns, but also against the human spliceosome, which is a validated drug target for the treatment of congenital diseases and cancers.
- Open Access
- 4 March 2022
- Published by Elsevier in Redox Biology
- Vol. 51, 102278
Biochemical and structural characterizations of thioredoxin reductase selenoproteins of the parasitic filarial nematodes Brugia malayi and Onchocerca volvulus
- 4 March 2022
- Published by Elsevier in Redox Biology
- Vol. 51, 102278
Open AccessBiochemical and structural characterizations of thioredoxin reductase selenoproteins of the parasitic filarial nematodes Brugia malayi and Onchocerca volvulus
- 1 August 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1864 (8) , 129617
A ring-shaped protein clusters gold nanoparticles acting as molecular scaffold for plasmonic surfaces
- 1 August 2020
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1864 (8) , 129617
A ring-shaped protein clusters gold nanoparticles acting as molecular scaffold for plasmonic surfaces
- 1 February 2020
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 147, 200-211
Ectopic suicide inhibition of thioredoxin glutathione reductase
- 1 February 2020
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 147, 200-211
Ectopic suicide inhibition of thioredoxin glutathione reductase
- 25 May 2018
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 13 (8) , 2190-2202
Fragment-Based Discovery of a Regulatory Site in Thioredoxin Glutathione Reductase Acting as “Doorstop” for NADPH Entry
Members of the FAD/NAD-linked reductase family are recognized as crucial targets in drug development for cancers, inflammatory disorders, and infectious diseases. However, individual FAD/NAD reductases are difficult to inhibit in a selective manner with off-target inhibition reducing usefulness of identified compounds. Thioredoxin glutathione reductase (TGR), a high molecular weight thioredoxin reductase-like enzyme, has emerged as a promising drug target for the treatment of schistosomiasis, a parasitosis afflicting more than 200 million people. Taking advantage of small molecules selected from a high-throughput screen and using X-ray crystallography, functional assays, and docking studies, we identify a critical secondary site of the enzyme. Compounds binding at this site interfere with well-known and conserved conformational changes associated with NADPH reduction, acting as a doorstop for cofactor entry. They selectively inhibit TGR from Schistosoma mansoni and are active against parasites in culture. Since many members of the FAD/NAD-linked reductase family have similar catalytic mechanisms, the unique mechanism of inhibition identified in this study for TGR broadly opens new routes to selectively inhibit homologous enzymes of central importance in numerous diseases.
- 25 May 2018
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 13 (8) , 2190-2202
Fragment-Based Discovery of a Regulatory Site in Thioredoxin Glutathione Reductase Acting as “Doorstop” for NADPH Entry
Members of the FAD/NAD-linked reductase family are recognized as crucial targets in drug development for cancers, inflammatory disorders, and infectious diseases. However, individual FAD/NAD reductases are difficult to inhibit in a selective manner with off-target inhibition reducing usefulness of identified compounds. Thioredoxin glutathione reductase (TGR), a high molecular weight thioredoxin reductase-like enzyme, has emerged as a promising drug target for the treatment of schistosomiasis, a parasitosis afflicting more than 200 million people. Taking advantage of small molecules selected from a high-throughput screen and using X-ray crystallography, functional assays, and docking studies, we identify a critical secondary site of the enzyme. Compounds binding at this site interfere with well-known and conserved conformational changes associated with NADPH reduction, acting as a doorstop for cofactor entry. They selectively inhibit TGR from Schistosoma mansoni and are active against parasites in culture. Since many members of the FAD/NAD-linked reductase family have similar catalytic mechanisms, the unique mechanism of inhibition identified in this study for TGR broadly opens new routes to selectively inhibit homologous enzymes of central importance in numerous diseases.